Effect of vitamin-D analogue on albuminuria in patients with non-dialysed chronic kidney disease stage 4-5: A retrospective single center study

BMC Nephrology

Volumn 13, Issue 1, 2012, Pages

  Jørgensen, Hanne Skou ^a   Winther, Simon ^a   Povlsen, Johan Vestergaard ^a   Ivarsen, Per ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Albuminuria; Alfacalcidol; Chronic kidney disease; Hyperparathyroidism; Vitamin D

Indexed keywords

ALFACALCIDOL; CREATININE; PHOSPHATE BINDING AGENT;

ADULT; AGED; ALBUMINURIA; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG EFFECT; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FUNCTION; MACROALBUMINURIA; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RETROSPECTIVE STUDY; SECONDARY HYPERPARATHYROIDISM; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ALBUMINURIA; CAUSALITY; COMORBIDITY; DENMARK; FEMALE; HUMANS; HYDROXYCHOLECALCIFEROLS; INCIDENCE; MALE; MIDDLE AGED; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; RETROSPECTIVE STUDIES; RISK ASSESSMENT; TREATMENT OUTCOME; VITAMIN D; VITAMINS; YOUNG ADULT;

EID: 84867583157     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-13-102     Document Type: Article

References (31)

1. Improving global outcomes in mineral and bone disorders. Moe SM, Drueke T, Clinical journal of the American Society of Nephrology: CJASN 2008 3 Suppl 3 127 S130 18988697
2. Retarding progression of chronic renal disease: the neglected issue of residual proteinuria. Ruggenenti P, Perna A, Remuzzi G, Kidney Int 2003 63 6 2254 2261 10.1046/j.1523-1755.2003.00033.x 12753315 (Pubitemid 36605839)
3. Proteinuria as a surrogate outcome in CKD: report of a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Levey AS, Cattran D, Friedman A, Miller WG, Sedor J, Tuttle K, et al. American journal of kidney diseases: the official journal of the National Kidney Foundation 2009 54 2 205 226 10.1053/j.ajkd.2009.04.029
4. Adverse effects of left ventricular hypertrophy in the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study. Boner G, Cooper ME, McCarroll K, Brenner BM, de Zeeuw D, Kowey PR, et al. Diabetologia 2005 48 10 1980 1987 16082528 (Pubitemid 41416906)
5. Proteinuria predicting outcome in renal disease: nondiabetic nephropathies (REIN). Remuzzi G, Chiurchiu C, Ruggenenti P, Kidney Int Suppl 2004 92 90 S96 15485427
6. Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Agarwal R, Acharya M, Tian J, Hippensteel RL, Melnick JZ, Qiu P, et al. Kidney Int 2005 68 6 2823 2828 10.1111/j.1523-1755.2005.00755.x 16316359 (Pubitemid 43251029)
7. Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial. Alborzi P, Patel NA, Peterson C, Bills JE, Bekele DM, Bunaye Z, et al. Hypertension 2008 52 2 249 255 10.1161/HYPERTENSIONAHA.108.113159 18606901
8. Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial. Fishbane S, Chittineni H, Packman M, Dutka P, Ali N, Durie N, American journal of kidney diseases: the official journal of the National Kidney Foundation 2009 54 4 647 652 10.1053/j.ajkd.2009.04.036
9. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. de Zeeuw D, Agarwal R, Amdahl M, Audhya P, Coyne D, Garimella T, et al. Lancet 2010 376 9752 1543 1551 10.1016/S0140-6736(10)61032-X 21055801
10. Oral calcitriol for reduction of proteinuria in patients with IgA nephropathy: a randomized controlled trial. Liu LJ, Lv JC, Shi SF, Chen YQ, Zhang H, Wang HY, American journal of kidney diseases: the official journal of the National Kidney Foundation 2012 59 1 67 74 10.1053/j.ajkd.2011.09.014
11. Low-dose alfacalcidol controls secondary hyperparathyroidism in predialysis chronic kidney disease. Reichel H, Nephron Clin Pract 2010 114 4 268 c276 10.1159/000276579 20090369
12. No difference between alfacalcidol and paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients: a randomized crossover trial. Hansen D, Rasmussen K, Danielsen H, Meyer-Hofmann H, Bacevicius E, Lauridsen TG, et al. Kidney Int 2011 80 8 841 850 10.1038/ki.2011.226 21832979
13. Effects of 1,25(OH)2D3 on compensatory renal growth in the growing rat. Matthias S, Busch R, Merke J, Mall G, Thomasset M, Ritz E, Kidney Int 1991 40 2 212 218 10.1038/ki.1991.202 1942769
14. Effect of 1,25 (OH)2 vitamin D3 on glomerulosclerosis in subtotally nephrectomized rats. Schwarz U, Amann K, Orth SR, Simonaviciene A, Wessels S, Ritz E, Kidney Int 1998 53 6 1696 1705 10.1046/j.1523-1755.1998.00951.x 9607202 (Pubitemid 28243754)
15. Effects of 1,25(OH)2D3 in experimental mesangial proliferative nephritis in rats. Panichi V, Migliori M, Taccola D, Filippi C, De Nisco L, Giovannini L, et al. Kidney Int 2001 60 1 87 95 10.1046/j.1523-1755.2001.00775.x 11422740 (Pubitemid 32587543)
16. A vitamin D analog ameliorates glomerular injury on rat glomerulonephritis. Makibayashi K, Tatematsu M, Hirata M, Fukushima N, Kusano K, Ohashi S, et al. Am J Pathol 2001 158 5 1733 1741 10.1016/S0002-9440(10)64129-6 11337371 (Pubitemid 32422938)
17. 1,25-Dihydroxyvitamin D3 decreases podocyte loss and podocyte hypertrophy in the subtotally nephrectomized rat. Kuhlmann A, Haas CS, Gross ML, Reulbach U, Holzinger M, Schwarz U, et al. Am J Physiol Renal Physiol 2004 286 3 526 F533 10.1152/ajprenal.00316.2003 14600034
18. Combination therapy with an angiotensin-converting enzyme inhibitor and a vitamin D analog suppresses the progression of renal insufficiency in uremic rats. Mizobuchi M, Morrissey J, Finch JL, Martin DR, Liapis H, Akizawa T, et al. Journal of the American Society of Nephrology: JASN 2007 18 6 1796 1806 10.1681/ASN.2006091028 17513326 (Pubitemid 46870316)
19. Renoprotective role of the vitamin D receptor in diabetic nephropathy. Zhang Z, Sun L, Wang Y, Ning G, Minto AW, Kong J, et al. Kidney Int 2008 73 2 163 171 10.1038/sj.ki.5002572 17928826
20. Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: blockade of compensatory renin increase. Zhang Z, Zhang Y, Ning G, Deb DK, Kong J, Li YC, Proc Natl Acad Sci USA 2008 105 41 15896 15901 10.1073/pnas.0803751105 18838678
21. Suppression of renin-angiotensin gene expression in the kidney by paricalcitol. Freundlich M, Quiroz Y, Zhang Z, Zhang Y, Bravo Y, Weisinger JR, et al. Kidney Int 2008 74 11 1394 1402 10.1038/ki.2008.408 18813285
22. Long-term therapeutic effect of vitamin D analog doxercalciferol on diabetic nephropathy: strong synergism with AT1 receptor antagonist. Zhang Y, Deb DK, Kong J, Ning G, Wang Y, Li G, et al. Am J Physiol Renal Physiol 2009 297 3 791 F801 10.1152/ajprenal.00247.2009 19535571
23. Active vitamin D and its analogue, 22-oxacalcitriol, ameliorate puromycin aminonucleoside-induced nephrosis in rats. Matsui I, Hamano T, Tomida K, Inoue K, Takabatake Y, Nagasawa Y, et al. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association-European Renal Association 2009 24 8 2354 2361 10.1093/ndt/gfp117
24. Combined vitamin D analog and AT1 receptor antagonist synergistically block the development of kidney disease in a model of type 2 diabetes. Deb DK, Sun T, Wong KE, Zhang Z, Ning G, Zhang Y, et al. Kidney Int 2010 77 11 1000 1009 10.1038/ki.2010.22 20182412
25. Effect of combination therapy with angiotensin receptor blocker and 1,25-dihydroxyvitamin D(3) in type 2 diabetic nephropathy in KK-A(y)/Ta mice. Ohara I, Tanimoto M, Gohda T, Yamazaki T, Hagiwara S, Murakoshi M, et al. Nephron Exp Nephrol 2011 117 4 124 e132 10.1159/000320284 20948237
26. Effects of 22-oxa-calcitriol on podocyte injury in adriamycin-induced nephrosis. Lydia A, Asanuma K, Nonaka K, Takagi M, Jeong KH, Kodama F, et al. Am J Nephrol 2012 35 1 58 68 10.1159/000334626 22189044
27. Effect of combining an ACE inhibitor and a VDR activator on glomerulosclerosis, proteinuria, and renal oxidative stress in uremic rats. Finch JL, Suarez EB, Husain K, Ferder L, Cardema MC, Glenn DJ, et al. Am J Physiol Renal Physiol 2012 302 1 141 F149 10.1152/ajprenal.00293.2011 21957179
28. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP, J Clin Invest 2002 110 2 229 238 12122115 (Pubitemid 34787360)
29. Paricalcitol attenuates renal interstitial fibrosis in obstructive nephropathy. Tan X, Li Y, Liu Y, Journal of the American Society of Nephrology: JASN 2006 17 12 3382 3393 10.1681/ASN.2006050520 17082242 (Pubitemid 44865281)
30. Oral calcitriol for the treatment of persistent proteinuria in immunoglobulin A nephropathy: an uncontrolled trial. Szeto CC, Chow KM, Kwan BC, Chung KY, Leung CB, Li PK, American journal of kidney diseases: the official journal of the National Kidney Foundation 2008 51 5 724 731 10.1053/j.ajkd.2007. 12.038 (Pubitemid 351626254)
31. ALTITUDE and the implications for ATMOSPHERE. McMurray J, Abraham W, Dickstein T, Køber L, Massie B, Krum AH, Eur J Heart Fail 2012 14 4 341 343 10.1093/eurjhf/hfs033 22431404